Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two naturally occurring prostaglandins—prostaglandin E1 (PGE1, also known as alprostadil) and prostaglandin I2 (PGI2, also known as prostacyclin or epoprostenol). Both are potent vasodilators with distinct but complementary mechanisms. Prostaglandin E1 acts primarily by relaxing vascular smooth muscle, leading to vasodilation and inhibition of platelet aggregation; it is used clinically for erectile dysfunction and to maintain ductus arteriosus patency in neonates with congenital heart defects[2][3][4]. Prostaglandin I2 (prostacyclin) is a strong vasodilator and inhibitor of platelet aggregation, widely used in the management of pulmonary arterial hypertension[4]. The combination may be considered for synergistic effects on vascular tone or platelet function but does not have a widely recognized brand name or fixed-dose formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prostaglandin E1 + prostaglandin I2.